Key Takeaways

• Always consult your veterinarian before combining EMS supplements with prescription medications to avoid dangerous interactions that can harm your horse’s kidneys, liver, or overall health
• Chasteberry significantly interferes with pergolide effectiveness, reducing ACTH control by competing for the same dopamine receptors in horses with both EMS and PPID
• SGLT2 inhibitors like ertugliflozin combined with NSAIDs dramatically increase acute kidney failure risk and require immediate NSAID discontinuation
• NEW 2024: Hyperlipaemia warning issued for SGLT2 inhibitors—21% of horses develop elevated triglycerides requiring enhanced monitoring
• Metformin has only 4-7% bioavailability in horses, making it largely ineffective for systemic insulin control but potentially helpful when given 30 minutes before feeding
• Levothyroxine requires strict concurrent diet restriction to work effectively and must be tapered gradually over four weeks to prevent dangerous metabolic rebound

Article Summary: Managing EMS requires careful coordination of supplements and medications. This comprehensive guide covers critical drug interactions, the 2024 SGLT2 inhibitor safety updates, real-world outcomes from 342 horse owners, and evidence-based protocols to keep your horse safe while maximizing treatment effectiveness.

Understanding EMS Supplement-Medication Safety

When you’re managing Equine Metabolic Syndrome in your horse, combining supplements with prescription medications isn’t as simple as adding ingredients to a recipe. Some combinations can block each other’s effects, while others create serious health risks that could land your horse in an emergency situation. Your horse’s safety depends on understanding which supplements and medications work together—and which ones absolutely don’t.

This guide walks you through the most critical drug interactions horse owners face when managing EMS, so you can make informed decisions that protect your horse while maximizing treatment effectiveness.

Why Drug Interactions Matter for EMS Horses

EMS horses often need multiple therapies working simultaneously. You might be using chasteberry for early PPID symptoms, chromium for insulin support, and prescription medications like pergolide or levothyroxine. Each substance affects how your horse’s body processes the others.

Research shows that certain supplement combinations can interfere with prescription medications, potentially leaving hormones uncontrolled even when you think your horse is properly medicated. The stakes are high: uncontrolled insulin levels mean laminitis risk, while kidney damage from drug interactions can become permanent.

Your veterinarian needs to know every single supplement your horse receives. Keep a written list updated with exact products, doses, and timing. This isn’t just good practice—it’s essential for preventing interactions that could compromise your horse’s treatment or health.

The Chasteberry-Pergolide Conflict You Need to Know

How This Interaction Happens

If your horse has both EMS and PPID (Cushing’s disease), you might be tempted to use chasteberry alongside pergolide. Don’t. Studies confirm that chasteberry directly interferes with pergolide’s ability to control ACTH levels because both substances compete for the same dopamine receptor binding sites in the brain.

Horses receiving both chasteberry and pergolide showed much higher ACTH levels than horses on pergolide alone, with the interference becoming particularly obvious during seasonal ACTH rises. Your horse might look better coat-wise, but the underlying pituitary tumor continues growing unchecked.

What This Means for Your Horse

Pergolide remains the gold standard PPID treatment because it actually controls abnormal hormone output from the pituitary gland. Chasteberry has never been documented to control pituitary hormone output, and now evidence shows it may block pergolide’s effectiveness.

If your horse is on pergolide, skip the chasteberry completely. If you’ve been using chasteberry and need to start pergolide, work with your vet to transition safely. The improved coat condition from chasteberry isn’t worth risking uncontrolled PPID progression.

Expert Perspective

According to Dr. Eleanor Kellon, who first published research on chasteberry use in PPID horses, “The bottom line here is that chasteberry alone is not an adequate treatment for PPID. Symptoms may improve for a while but the abnormal growth in the pituitary goes unchecked and when chasteberry stops working the process is much more difficult to get under control.”

SGLT2 Inhibitors and NSAIDs: A Dangerous Kidney Combination

Understanding the Kidney Risk

SGLT2 inhibitors (ertugliflozin, canagliflozin, dapagliflozin) represent breakthrough treatments for refractory insulin resistance in EMS horses. However, combining these medications with NSAIDs creates a perfect storm for acute kidney injury.

Ertugliflozin increases the risk of renal failure when administered concurrently with nonsteroidal anti-inflammatory drugs like phenylbutazone or firocoxib. The mechanism involves multiple factors: SGLT2 inhibitors cause mild dehydration through glucose excretion in urine, while NSAIDs reduce kidney blood flow. Together, they can trigger acute kidney damage.

Clinical Reality and Solutions

In a retrospective study of 51 horses with hyperinsulinemia-associated laminitis treated with ertugliflozin, the drug allowed stopping NSAID treatment in almost all cases within 2 weeks as laminitis pain improved. This creates a natural solution: the SGLT2 inhibitor reduces laminitis pain so effectively that NSAIDs become unnecessary.

If your horse is starting an SGLT2 inhibitor:

• Discontinue NSAIDs immediately unless your vet determines they’re absolutely essential
• Ensure unlimited access to fresh water
• Provide guaranteed salt intake to prevent dehydration
• Schedule bloodwork to monitor kidney function (BUN, creatinine) and triglyceride levels

Horses must be screened for renal function before starting SGLT2 inhibitors, and the increased risk with concurrent NSAID use means these drugs should not be combined in laminitis cases.

2024 SGLT2 Inhibitor Safety Update: Critical Hyperlipaemia WarningNEW 2024

⚠️ CRITICAL UPDATE: In September 2024, a group of leading UK veterinarians published urgent safety recommendations after several horses developed hyperlipaemia while receiving SGLT2 inhibitor treatment. This isn’t a reason to panic if your horse is doing well on these medications, but it does mean you need to understand the risks and follow proper protocols.

Understanding the Hyperlipaemia Risk

Hyperlipaemia occurs when fat levels in the blood become dangerously high, potentially causing liver damage and other serious complications. While SGLT2 inhibitors cause a predictable, usually harmless increase in triglycerides, some horses develop severe hyperlipaemia requiring immediate intervention.

A January 2025 study tracking 58 horses found that 21% had triglyceride levels above 2.0 mmol/L at day 30 of treatment, with the highest recorded level reaching 10.8 mmol/L. Most horses showed no clinical signs despite elevated triglycerides, but this doesn’t mean the risk should be ignored.

Who’s Most at Risk?

Horses most likely to develop problematic hyperlipaemia on SGLT2 inhibitors include:

• Ponies and miniature horses
• Horses with uncontrolled PPID
• Animals on inadequately restricted diets
• Horses already experiencing rapid weight loss
• Those with baseline high triglycerides or insulin levels

Research shows that day 30 triglyceride levels correlate with baseline insulin levels and baseline triglyceride concentrations, meaning horses starting with higher values face greater risk.

The 2024 UK Veterinary Recommendations

Based on the September 2024 safety review, SGLT2 inhibitors should only be used when:

1. Diet and exercise management has failed after appropriate implementation (minimum 30 days documented)
2. Active laminitis is present and requires rapid intervention
3. Owners are fully informed about hyperlipaemia risks and clinical signs to watch for
4. Regular monitoring can be maintained throughout treatment

This represents a shift from viewing SGLT2 inhibitors as a first-line option to recognizing them as powerful medications reserved for cases that truly need them.

Clinical Signs of Hyperlipaemia You Must Know

Contact your veterinarian immediately if your horse on SGLT2 inhibitors shows:

• Loss of appetite or refusing feed
• Depression or unusual lethargy
• Colic signs (pawing, looking at flanks, lying down excessively)
• Muscle tremors or weakness
• Rapid weight loss (more than 1% body weight per week)

One horse in the January 2025 study experienced colic and inappetence shortly after starting dapagliflozin, demonstrating that problems can emerge early in treatment.

Mandatory Pre-Treatment Checklist

Before starting any SGLT2 inhibitor, verify every item on this checklist:

Requirement	Why It Matters	How to Verify
Diet trial completed	SGLT2i should never replace proper diet management	Minimum 30 days documented low-NSC feeding
PPID controlled (if present)	Uncontrolled PPID increases hyperlipaemia risk	ACTH within target range on adequate pergolide dose
Baseline bloodwork	Establishes starting triglycerides and organ function	Triglycerides, BUN, creatinine, liver enzymes, baseline insulin
Water access confirmed	SGLT2i cause increased urination requiring more water	Automatic waterers functional, multiple water sources available
Salt supplementation plan	Prevents dehydration from glucose-induced diuresis	30-60g daily salt in feed or free-choice loose salt
Owner education completed	Early recognition of problems saves horses	Written information on hyperlipaemia signs provided

Lipid Profile Changes: What’s Normal vs. Concerning

Recent research mapping lipid changes during SGLT2 inhibitor treatment found several predictable patterns:

Expected changes (usually not problematic):

• Triglycerides increase from median 0.5 mmol/L to 1.0 mmol/L by day 30
• Total cholesterol rises from 2.36 mmol/L to 2.84 mmol/L
• HDL percentage decreases slightly (52.4% to 50%)
• VLDL percentage increases (10.4% to 12.3%)
• Beta-hydroxybutyrate increases modestly

Concerning changes requiring action:

• Triglycerides above 2.0 mmol/L
• Rapid triglyceride increase between tests
• Clinical signs appearing alongside elevated values
• Triglycerides continuing to rise after day 30

Managing Elevated Triglycerides

If your horse’s triglycerides rise above 2.0 mmol/L while on SGLT2 inhibitors:

1. Verify diet is truly restricted. Cases where diet and PPID weren’t fully controlled showed both increased insulin and problematic triglycerides.
2. Consider dose reduction. Lower SGLT2 inhibitor doses may control insulin adequately while reducing triglyceride stress, though insulin may increase slightly.
3. Increase monitoring frequency. Recheck triglycerides weekly until stable or decreasing.
4. Watch for clinical signs. Asymptomatic hypertriglyceridemia is common; clinical signs change everything.
5. Consult your veterinarian about continuing treatment. Risk-benefit analysis differs for each horse.

The dose-effect relationship matters: as canagliflozin doses decreased due to high triglycerides in one study, insulin concentrations increased, highlighting the balancing act between efficacy and safety.

Enhanced Monitoring Protocol (2024 Standards)

The January 2025 research and September 2024 safety recommendations establish this monitoring schedule:

Timepoint	Tests Required	Action Thresholds
Day 0 (baseline)	Insulin, glucose, triglycerides, BUN, creatinine, liver enzymes	Establish baseline; postpone if triglycerides >1.5 mmol/L
Day 7	Triglycerides, clinical assessment	If triglycerides doubled from baseline, increase monitoring
Day 30	Complete panel (insulin, triglycerides, kidney/liver function)	Triglycerides >2.0 mmol/L = consider dose reduction
Monthly thereafter	Insulin, triglycerides	Watch for insulin increases indicating tolerance development
If rapid weight loss	Immediate triglyceride check	Rule out hyperlipaemia before assuming treatment success

The Bottom Line on SGLT2 Inhibitor Safety

SGLT2 inhibitors remain the most effective pharmacological option for severe insulin dysregulation and hyperinsulinaemia-associated laminitis. The 2024 safety data doesn’t change that. What has changed is our understanding that these are powerful medications requiring proper case selection, comprehensive monitoring, and immediate response to warning signs.

SGLT2 inhibitors work brilliantly when used correctly in appropriate cases with proper oversight. They fail catastrophically when used as diet replacements or without adequate monitoring. Make sure your case qualifies for treatment, commit to the monitoring schedule, and stay vigilant for problems.

Real-World SGLT2 Inhibitor Outcomes: What 342 Horse Owners ReportNEW 2024

Clinical trials tell us what happens under controlled conditions. Real-world data tells us what happens in your barn. A 2024 survey of 342 horse owners using SGLT2 inhibitors provides crucial insights into how these medications actually perform when managing EMS horses day-to-day.

Owner Satisfaction: The Numbers

The results surprised even researchers. Among owners whose horses completed SGLT2 inhibitor treatment:

• 64.7% were extremely satisfied with the treatment outcome
• 21.2% were somewhat satisfied, bringing total satisfaction to 85.9%
• 69.6% would be extremely likely to recommend SGLT2i to other owners
• 17.3% would be somewhat likely to recommend treatment

These satisfaction rates held steady regardless of which SGLT2 inhibitor was used, with no significant differences between dapagliflozin (94.4%), canagliflozin (93.5%), ertugliflozin tablets (84.4%), and ertugliflozin paste (83.2%).

The Desperation Factor: Euthanasia Consideration

Perhaps the most powerful statistic: 22.5% of owners (77 horses) had considered euthanasia before starting SGLT2 inhibitor treatment. This reveals the severity of cases turning to these medications—horses whose laminitis pain and metabolic dysfunction had reached crisis levels despite owners’ best efforts with diet and management.

For these critically affected horses, SGLT2 inhibitors represented a last-resort option. The high satisfaction rates among this group demonstrate that these medications can genuinely save horses that conventional management cannot help.

Why Owners Used SGLT2 Inhibitors

The survey documented specific reasons owners started treatment:

Indication	Percentage of Cases	What This Means
High insulin concentrations	84.2%	Primary metabolic management
Active laminitis	59.7%	Acute crisis intervention
Considered euthanasia	22.5%	End-stage desperation cases

Many horses had multiple indications, explaining why percentages exceed 100%. The overlap between high insulin and active laminitis reflects the reality that these conditions frequently occur together in severe EMS cases.

Geographic Usage Patterns

SGLT2 inhibitor use varies dramatically by location:

• Australia: 54.1% of surveyed users (185 horses)
• United Kingdom: 32.2% (110 horses)
• United States: 8.5% (29 horses)
• Canada: 2.6% (9 horses)
• Europe: 1.8% (6 horses)

These geographic differences likely reflect medication availability, veterinary prescribing patterns, and regulatory environments rather than differences in horse populations or EMS prevalence.

Which SGLT2 Inhibitors Are Actually Being Used?

Among the 342 surveyed horses:

• Ertugliflozin: 79.8% (overwhelmingly most common)
• Canagliflozin: 13.5%
• Other formulations: 6.7% (including dapagliflozin)

Ertugliflozin’s dominance likely stems from its lower effective dose (0.05 mg/kg vs. 0.3-0.6 mg/kg for canagliflozin), making it more cost-effective, and its availability through compounding pharmacies in regions where human formulations are expensive or restricted.

Owner Concerns: The Four Major Themes

Despite high satisfaction, owners expressed legitimate worries falling into four categories:

1. Safety and Side Effects (14.3% of owners)

Concerns centered on:

• Lack of long-term safety data in horses
• Triglyceride elevation risks
• Potential for urinary tract infections
• Unknown effects of prolonged use

These concerns are valid—SGLT2 inhibitors have limited equine safety data compared to established medications like pergolide.

2. Medication Cost

SGLT2 inhibitors represent a significant ongoing expense. Monthly costs vary by:

• Which medication is used (ertugliflozin typically most affordable)
• Horse’s body weight (dose is weight-based)
• Source (compounding pharmacy vs. human formulation)
• Geographic location and availability

For many owners, cost determines whether treatment is sustainable long-term.

3. Medication Availability

Availability challenges include:

• Compounding pharmacy supply interruptions
• Regional regulatory restrictions
• Prescription requirements varying by location
• Import/export limitations for human medications

4. Long-Term Efficacy Questions

Owners worried about:

• Whether the medication would continue working indefinitely
• Development of tolerance or resistance
• What happens when treatment must be discontinued
• Lack of exit strategy protocols

These concerns have merit—research shows 16% of horses experienced insulin increases beyond 30 days of ertugliflozin treatment, possibly due to compensatory SGLT1 receptor activity or management lapses.

What This Means for Your Decision

The real-world data tells a nuanced story:

SGLT2 inhibitors deliver exceptional results for severe cases where horses face euthanasia due to uncontrolled laminitis and insulin dysregulation. Satisfaction rates above 85% among desperate cases represent genuinely life-saving outcomes.

However, these medications aren’t magic bullets. Owner concerns about safety, cost, availability, and long-term efficacy reflect real limitations that must factor into treatment decisions.

If your horse fits the profile—refractory hyperinsulinaemia despite proper management, active laminitis causing severe suffering, or euthanasia consideration—SGLT2 inhibitors offer hope backed by both clinical data and real-world owner experiences. But commit to proper monitoring, understand the costs, and have realistic expectations about duration of effectiveness.

Dapagliflozin: The Newest SGLT2 Inhibitor OptionNEW 2025

While ertugliflozin and canagliflozin have dominated SGLT2 inhibitor use in horses, dapagliflozin is emerging as a third option. A January 2025 head-to-head comparison study provides the first direct evidence comparing dapagliflozin and ertugliflozin efficacy and safety.

Dapagliflozin vs. Ertugliflozin: The Data

The study tracked 58 hyperinsulinemic horses: 34 received dapagliflozin (0.02 mg/kg once daily) and 24 received ertugliflozin (0.05 mg/kg once daily). Results after 30 days showed:

Insulin reduction (both drugs equally effective):

• Median insulin dropped from 170 μIU/mL to 28.7 μIU/mL
• No significant difference between dapagliflozin and ertugliflozin groups
• Both medications dramatically reduced hyperinsulinaemia

Laminitis improvement:

• Modified Obel lameness grades decreased significantly with both drugs
• Pain reduction allowed NSAID discontinuation in most cases
• No difference in lameness improvement between the two drugs

Lipid profile changes (identical patterns):

• Triglycerides increased from 0.5 to 1.0 mmol/L (both drugs)
• Total cholesterol increased from 2.36 to 2.84 mmol/L
• HDL percentage decreased; VLDL percentage increased
• 21% of all cases had triglycerides >2.0 mmol/L at day 30
• No significant differences in lipid changes between dapagliflozin and ertugliflozin

Choosing Between SGLT2 Inhibitors

Since efficacy appears similar across ertugliflozin, dapagliflozin, and canagliflozin, choice depends on practical factors:

Factor	Ertugliflozin	Dapagliflozin	Canagliflozin
Typical Dose	0.05 mg/kg	0.02 mg/kg	0.3-0.6 mg/kg
Cost (500kg horse)	Lower (25mg daily)	Lowest (10mg daily)	Higher (150-300mg daily)
Availability	Widely compounded	Limited compounding	Human tablets available
Usage Data	Most extensive (79.8% of users)	Emerging data	Moderate data (13.5% of users)
PU/PD Reports	Yes (16% of cases)	Not extensively documented	Yes (anecdotal)

The January 2025 research confirms what clinicians suspected: the different SGLT2 inhibitors work through identical mechanisms and produce essentially the same results. Choose based on availability, cost, and veterinary preference rather than expecting one to outperform others.

Velagliflozin: The Fourth Option

Velagliflozin deserves mention as the only SGLT2 inhibitor actually licensed for veterinary use (in cats with diabetes). Limited equine research shows it reduces insulin effectively at 0.3 mg/kg once daily, with one unique advantage: polyuria/polydipsia has not been reported with velagliflozin use, unlike other SGLT2 inhibitors.

However, velagliflozin availability for horses remains limited, and receptor selectivity data aren’t published, making it difficult to predict whether it offers meaningful advantages over the more commonly used options.

Long-Term SGLT2 Inhibitor Efficacy: What to Expect Beyond 30 DaysNEW 2024

Most SGLT2 inhibitor research focuses on the first 30 days of treatment. But what happens month two, month six, or year one? Emerging data reveals important patterns you need to understand before starting long-term treatment.

The Tolerance Problem: When Insulin Creeps Back Up

A retrospective study of 51 horses treated with ertugliflozin found that 8 horses (approximately 16%) showed insulin increases beyond the initial 30-day treatment period, despite continuing medication at the same dose.

Two potential mechanisms explain this concerning pattern:

1. SGLT1 Receptor Compensation: When SGLT2 receptors are blocked long-term, SGLT1 receptors (responsible for 10% of kidney glucose reabsorption) may compensate by increasing activity, allowing more glucose reabsorption and driving insulin back up.
2. Management Drift: Owners may unconsciously relax dietary restrictions once the horse improves, or PPID control may slip, allowing insulin to rise despite continued medication.

Recognizing Decreasing Efficacy

Watch for these signs that SGLT2 inhibitor effectiveness may be declining:

• Increased digital pulses returning after months of normal pulses
• Weight loss plateauing or weight gain beginning
• Subtle changes in movement willingness or comfort
• Insulin levels rising on follow-up testing
• Increased sensitivity to grass or diet changes

Most horses maintain good insulin control for months or years on SGLT2 inhibitors, but the 16% who develop tolerance require vigilance to catch early.

Response Strategies When Efficacy Declines

If your horse’s insulin increases while on SGLT2 inhibitor treatment:

1. First: Verify management hasn’t slipped
   • Is diet still properly restricted?
   • Has hay NSC content changed with new batch?
   • Is PPID still controlled with adequate pergolide?
   • Has exercise decreased?
2. Second: Consider dose adjustment
   • Some horses respond to modest dose increases
   • Balance against triglyceride effects
   • Not all horses tolerate higher doses safely
3. Third: Add complementary strategies
   • Metformin given 30-60 minutes before feeding
   • Levothyroxine if weight-loss resistant
   • Further dietary carbohydrate restriction
4. Fourth: Switch SGLT2 inhibitors
   • Limited evidence but some horses respond differently
   • Try different drug from same class
   • Monitor response after 14-30 days

Long-Term Monitoring Schedule

Based on the tolerance development data, adjust your monitoring beyond the initial 30 days:

Timeframe	Testing Frequency	What to Monitor
Months 1-3	Monthly	Insulin, triglycerides, clinical signs
Months 4-6	Every 6-8 weeks	Insulin, periodic triglyceride checks
Beyond 6 months	Every 3 months	Insulin, annual triglyceride/organ function panel
Any time signs change	Immediate	Complete metabolic panel

Is Indefinite Treatment Safe?

We don’t have decades of equine safety data yet. What we know:

• Treatment periods of 6-18 months appear well-tolerated in most horses
• No catastrophic long-term effects identified in current data
• Triglyceride elevation remains the primary concern
• Cost often limits treatment duration more than safety concerns

Many horses need SGLT2 inhibitors indefinitely because their insulin dysregulation never resolves with diet alone. Work with your veterinarian to balance the very real benefits against unknown long-term risks, monitoring carefully for any emerging problems.

Levothyroxine: Not a Standalone Solution

The Diet Dependency

Many horse owners view levothyroxine as a “weight loss pill” for their EMS horses. It’s not that simple. Research clearly shows that levothyroxine induces weight loss and reduces neck circumference in EMS horses when animals are kept on a weight maintenance diet, but does not influence glucose dynamics or insulin sensitivity.

Translation: Levothyroxine won’t fix your horse’s insulin problems. It works by increasing metabolic rate, which burns more calories—but only if you’re simultaneously restricting calorie intake. Feed your horse ad libitum hay while on levothyroxine, and you’ll simply have a horse eating more to match the increased metabolism.

Safe Levothyroxine Use Protocol

Levothyroxine treatment should be administered at 0.1-0.15 mg/kg levothyroxine sodium once daily orally until an appropriate body condition is attained or for a maximum of 6 months. For a 500kg horse, that’s 48-72mg daily.

Critical tapering requirement: Horses must be weaned off levothyroxine at the end of the treatment period by decreasing the dose by half for 2 weeks and then a quarter for 2 weeks. Sudden discontinuation can trigger metabolic rebound that puts your horse at risk for laminitis.

When to Consider Levothyroxine

Levothyroxine makes sense for “weight-loss resistant” horses—those who remain obese despite strict diet and exercise for 30+ days. It accelerates fat loss in these frustrating cases, but you must maintain dietary restriction throughout treatment and beyond.

Metformin: Understanding Its Limited Role

The Bioavailability Problem

Metformin seems like it should work brilliantly for EMS horses. In humans, it’s a diabetes management cornerstone. In horses, there’s a massive problem: bioavailability was determined to be approximately 7.1% in unfed horses and 3.9% in fed horses.

Less than 8% of the metformin you give your horse actually gets absorbed into the bloodstream. This explains why metformin does not have systemic effects on insulin sensitivity in horses despite having some benefit on reducing post-meal insulin spikes.

How Metformin Actually Works in Horses

Instead of systemic effects, metformin has a direct effect on the enterocyte (intestinal cells) and decreases enteric glucose absorption, consequently reducing the insulin response to oral glucose in horses. It works locally in the gut, not systemically like in humans.

Practical application: Give metformin 30-60 minutes before feeding to maximize its gut-level effect on blocking glucose absorption. Response to metformin can be evaluated by performing an oral sugar test 30-60 minutes after drug administration to assess benefits in the individual patient.

Quick Reference: Critical EMS Supplement-Medication Interactions (2025 Updated)UPDATED

Supplement/Medication	Interacts With	Risk Level	What Happens	Action Required	2024-2025 Updates
Chasteberry	Pergolide (Prascend)	HIGH	Blocks pergolide effectiveness by competing for dopamine receptors; ACTH stays elevated despite treatment	Choose one or the other – never combine	Mechanism confirmed in multiple studies; avoid combination therapy
SGLT2 Inhibitors (Ertugliflozin, Canagliflozin, Dapagliflozin)	NSAIDs (Bute, Firocoxib, Flunixin)	HIGH	Dramatically increases acute kidney injury risk through combined dehydration + reduced kidney blood flow	Stop NSAIDs when starting SGLT2i; monitor kidney function closely; ensure unlimited water access	Most horses can discontinue NSAIDs within 2 weeks as laminitis pain resolves on SGLT2i
SGLT2 Inhibitors	Inadequate Diet Control	HIGH	Hyperlipaemia risk increases; insulin may remain elevated or return despite medication	NEW 2024: Document 30-day diet trial failure before starting; maintain strict diet during treatment	September 2024 UK veterinary warning: Use only after diet failure or in active laminitis cases
SGLT2 Inhibitors	Uncontrolled PPID	MEDIUM-HIGH	Increased hyperlipaemia risk; reduced treatment effectiveness	Control PPID with adequate pergolide dose before starting SGLT2i; monitor ACTH regularly	2024 data shows cases with uncontrolled PPID have worse outcomes
Levothyroxine	High-calorie diet / Inadequate calorie restriction	MEDIUM	Ineffective for weight loss; may increase appetite making management harder	Must combine with strict calorie control; monitor for increased appetite	Confirmed: increases metabolic rate but doesn’t improve insulin sensitivity
Metformin	N/A (poor absorption)	LOW	Limited systemic effects due to only 3.9-7.1% bioavailability; works locally in gut	Give 30-60 min before feeding for best results; don’t expect dramatic insulin changes	No new safety concerns; continues to have supportive role only
Chromium/Magnesium	Various medications	LOW	Generally safe but limited efficacy evidence for insulin improvement	Inform vet of use; not reliable as sole treatment	No new interactions identified; evidence for efficacy remains limited

Supplement Timing Strategies to Avoid Interactions

Create a Medication Schedule

Write out your horse’s complete medication and supplement schedule hour by hour. Some combinations work fine if separated by 2-4 hours, even if they shouldn’t be given simultaneously.

Sample safe timing protocol:

• 7:00 AM: Pergolide with morning feed
• 7:30 AM: Chromium and magnesium supplements
• 11:00 AM: Metformin (30 minutes before lunch hay)
• 11:30 AM: Lunch hay
• 4:30 PM: Metformin (30 minutes before dinner)
• 5:00 PM: Dinner with levothyroxine and balancer
• 10:00 PM: Late-night hay

Monitor and Document

Keep a log of:

• All supplements with exact brand names and doses
• Prescription medications and timing
• Any changes in behavior, appetite, or hoof comfort
• Scheduled bloodwork results

Share this log with your veterinarian at every visit. Patterns often emerge that help fine-tune your horse’s protocol.

When to Call Your Veterinarian Immediately

Watch for these red flags that indicate a potential drug interaction or adverse reaction:

Kidney-related warnings:

• Decreased urination or very dark urine
• Swelling in lower legs
• Loss of appetite
• Depression or lethargy

Metabolic crisis signs:

• Sudden onset or worsening lameness
• Increased digital pulses
• Reluctance to move
• Lying down more than normal

Thyroid oversupplementation:

• Excessive sweating
• Rapid heart rate (>48 bpm at rest)
• Anxiety or nervousness
• Rapid weight loss with good appetite

Hyperlipaemia signs (for horses on SGLT2 inhibitors):

• Loss of appetite or refusing feed
• Colic signs
• Muscle tremors
• Rapid weight loss (>1% body weight/week)

Monitoring Requirements for Common EMS Medication CombinationsUPDATED 2025

Medication/Supplement	Recommended Monitoring	Frequency	Key Parameters	Critical Thresholds
SGLT2 Inhibitors (All Types)	Blood chemistry panel + insulin	Days 0, 7, 30, then monthly for 3 months, then every 3 months	Insulin, triglycerides, BUN, creatinine, liver enzymes, clinical assessment	Triglycerides >2.0 mmol/L = increase monitoring; >5.0 mmol/L = consider dose reduction or discontinuation
Pergolide	ACTH testing	6-8 weeks after dose changes; seasonally (Aug-Oct for baseline, consider month-specific reference ranges)	ACTH levels, clinical signs (coat, muscle, energy, laminitis risk)	ACTH >35 pg/mL (Sep-Oct) or above seasonal reference range = increase dose
Levothyroxine	Body condition scoring, insulin testing, T4 levels (optional)	Monthly BCS; insulin test every 6-8 weeks; T4 only if signs of over/under-supplementation	Weight loss rate (target 1% body weight/week max), resting insulin, heart rate, attitude	Heart rate >48 bpm at rest, anxiety, excessive sweating = possible oversupplementation
Metformin	Post-prandial insulin test	2-4 weeks after starting; repeat every 8-12 weeks if continuing	Insulin 2 hours after feeding (with and without medication for comparison)	No established threshold; assess individual response to determine if beneficial
Chromium/Magnesium	Insulin dynamics testing	8-12 weeks after starting; not all horses require ongoing monitoring	Oral sugar test or resting insulin	Limited evidence for specific thresholds; monitor clinical improvement
SGLT2i + Pergolide (EMS + PPID)	Combined ACTH + metabolic panel	Monthly for first 3 months, then every 2-3 months	ACTH, insulin, triglycerides, kidney/liver function	Both ACTH and insulin must be controlled; triglycerides >2.0 mmol/L may require intervention
SGLT2i + Levothyroxine	Metabolic panel + clinical assessment	Every 4-6 weeks during concurrent use	Insulin, triglycerides, body weight, heart rate, clinical signs	Weight loss >1%/week = reduce levothyroxine; triglycerides >2.0 mmol/L = consider SGLT2i dose reduction

Important note on monitoring costs: Regular bloodwork represents a significant expense, but it’s essential for safe long-term medication use. Discuss with your veterinarian which tests are absolutely necessary versus optional for your horse’s specific situation to balance safety with budget constraints.

Building Your Veterinary Partnership

Information Your Vet Needs

Come to appointments prepared with:

• Complete list of current supplements (brands, doses, timing)
• All prescription medications
• Recent changes in management or diet
• Photos or videos of any concerning symptoms
• Questions written down in advance

Questions to Ask Your Vet

• “Are there any interactions between [supplement X] and [medication Y]?”
• “What signs should I watch for that indicate a problem?”
• “How will we monitor whether this combination is working?”
• “What’s our backup plan if this approach doesn’t work?”
• “Should we adjust timing to minimize interactions?”

The Role of Supplements vs. Medications in EMS Management

Medications: Targeted Hormonal Control

Prescription medications like pergolide, SGLT2 inhibitors, and levothyroxine directly modify hormone levels or metabolic rate. They’re powerful tools with specific indications and require veterinary monitoring.

Supplements: Supporting Nutritional Needs

Chromium, magnesium, antioxidants, and similar supplements provide nutritional support. While evidence for chromium and magnesium improving insulin sensitivity in horses is limited from experimental studies, they’re generally safe at recommended doses. Don’t rely on supplements alone to manage EMS—they’re supportive, not curative.

The foundation remains diet and exercise. No medication or supplement substitutes for proper calorie control, low-NSC forage, and appropriate exercise. Everything else enhances these fundamentals but can’t replace them.

Special Considerations for Horses with Multiple Conditions

EMS + PPID Combination

Older horses often have both conditions. When PPID has been diagnosed, pergolide treatment is recommended to minimize the effects of PPID on insulin dysregulation. Control the PPID first with pergolide alone, then address remaining insulin issues with appropriate EMS management.

EMS + Active Laminitis

During acute laminitis episodes, pain control becomes crucial. However, SGLT2 inhibitor treatment often eliminates the need for NSAIDs within 2 weeks as insulin-driven inflammation resolves. Work with your vet to minimize NSAID duration while the SGLT2 inhibitor takes effect.

Weight-Loss Resistant Cases

Some horses stay obese despite perfect diet management. These frustrating cases benefit from levothyroxine at 0.1 mg/kg daily for 3-6 months to accelerate fat loss, but only when combined with continued dietary restriction. Don’t expect magic—levothyroxine amplifies diet efforts but doesn’t replace them.

Conclusion

Managing EMS medications and supplements safely requires knowledge, vigilance, and close veterinary partnership. The most dangerous assumption you can make is that “natural” supplements are automatically safe to combine with prescriptions. Chasteberry blocking pergolide and NSAIDs damaging kidneys when combined with SGLT2 inhibitors prove that interactions matter enormously.

The 2024-2025 updates on SGLT2 inhibitor safety underscore this reality: these breakthrough medications save horses’ lives when used correctly, but require proper case selection, comprehensive monitoring, and immediate response to warning signs like hyperlipaemia.

Start by listing every single supplement and medication your horse receives. Review this list with your veterinarian and create a timing strategy that maximizes benefits while minimizing risks. Monitor your horse closely for any changes, and don’t hesitate to call your vet if something seems off.

Your horse’s safety depends on informed decision-making. With the right knowledge and veterinary support, you can navigate the complex world of EMS medications and supplements confidently, giving your horse the best chance at metabolic stability and freedom from laminitis.

EMS Supplement Medication Interactions FAQs

Can I give my EMS horse chasteberry if he’s on pergolide for Cushing’s?

No, you should not combine chasteberry with pergolide. Research shows that chasteberry interferes with pergolide’s effectiveness by competing for the same dopamine receptors, resulting in higher ACTH levels even though clinical symptoms like coat quality may improve. Choose pergolide for PPID control and skip the chasteberry.

Is it safe to use bute with EMS supplement medication interactions like SGLT2 inhibitors?

Combining NSAIDs like phenylbutazone with SGLT2 inhibitors dramatically increases the risk of acute kidney failure. Fortunately, most horses can discontinue NSAIDs within 2 weeks of starting SGLT2 inhibitor treatment as laminitis pain resolves. Always inform your vet if your horse needs both classes of drugs simultaneously.

Why isn’t metformin working for my horse’s insulin levels?

Metformin has very poor bioavailability in horses at only 3.9-7.1%, meaning most of the drug never enters the bloodstream. Instead, metformin works locally in the intestinal tract to decrease glucose absorption rather than having systemic effects on insulin sensitivity. Give it 30-60 minutes before feeding for best results, but don’t expect dramatic insulin improvements.

How long can my EMS horse stay on levothyroxine safely?

Levothyroxine should be used for a maximum of 6 months to accelerate weight loss, then gradually tapered by reducing the dose by half for 2 weeks, then by half again for another 2 weeks before stopping. Never stop levothyroxine abruptly, especially in horses at risk for laminitis, as this can trigger dangerous metabolic rebound.

Do chromium and magnesium supplements interact with EMS medications?

Chromium and magnesium supplements are generally safe to use alongside EMS medications without major interactions. However, evidence supporting their efficacy for improving insulin sensitivity in horses remains limited from experimental studies, so they should not be relied upon as primary treatment and your veterinarian should be informed of their use.

What is hyperlipaemia and why does it matter for horses on SGLT2 inhibitors?NEW 2024

Hyperlipaemia is a dangerous condition where fat levels in the blood become extremely high, potentially causing liver damage and other serious complications. While SGLT2 inhibitors predictably increase triglycerides in most horses (usually safely), some develop severe hyperlipaemia requiring treatment changes or discontinuation. September 2024 veterinary warnings emphasize that horses on SGLT2 inhibitors need regular triglyceride monitoring, with levels above 2.0 mmol/L triggering increased vigilance and levels above 5.0 mmol/L potentially requiring dose reduction or stopping the medication.

Is dapagliflozin better than ertugliflozin for EMS horses?NEW 2025

No, research shows dapagliflozin and ertugliflozin are equally effective at reducing insulin and improving laminitis, with identical lipid profile effects and no significant differences in outcomes. The choice between different SGLT2 inhibitors should be based on practical factors like cost, availability, and veterinary preference rather than expecting one to outperform the others. Dapagliflozin requires a lower dose (0.02 mg/kg vs. 0.05 mg/kg for ertugliflozin), potentially reducing costs, but availability through compounding pharmacies may be more limited.

Why did my horse’s insulin go back up after months on ertugliflozin?NEW 2024

Approximately 16% of horses on ertugliflozin show insulin increases beyond the initial 30-day treatment period despite continuing medication. This happens either because SGLT1 receptors compensate by increasing glucose reabsorption when SGLT2 receptors are blocked long-term, or because dietary management has inadvertently slipped. First verify that diet remains properly restricted and PPID (if present) stays controlled with adequate pergolide, then consult your veterinarian about dose adjustment, adding complementary strategies like metformin, or potentially switching to a different SGLT2 inhibitor.

Can I use SGLT2 inhibitors if my horse has both PPID and EMS?NEW 2024

Yes, SGLT2 inhibitors can be used in horses with both PPID and EMS, but PPID must be adequately controlled with pergolide first. Research shows that horses with uncontrolled PPID have increased risk of hyperlipaemia on SGLT2 inhibitors and reduced treatment effectiveness. Your veterinarian should verify ACTH levels are within target range before starting an SGLT2 inhibitor, then monitor both conditions regularly. Combined therapy requires more intensive monitoring, with monthly bloodwork for the first three months checking both ACTH and metabolic parameters including insulin, triglycerides, and kidney/liver function.

What should I do if my horse develops signs of hyperlipaemia on SGLT2 inhibitors?NEW 2024

Contact your veterinarian immediately if your horse shows loss of appetite, depression, colic signs (pawing, looking at flanks, lying down excessively), muscle tremors, or rapid weight loss while on SGLT2 inhibitor treatment. These may indicate hyperlipaemia developing. Your vet will likely perform emergency bloodwork to check triglyceride levels and organ function, then determine whether to reduce the SGLT2 inhibitor dose, discontinue it, or implement supportive treatments. Early recognition and rapid response are crucial because severe hyperlipaemia can cause life-threatening liver damage if not addressed promptly.

EMS Supplement Medication Interactions Citations

1. Warning to Horse Owners: Use Caution Mixing Chastetree Berries with Pergolide – EquiMed
2. Treating PPID: the pill or the plant? – Understanding Laminitis
3. Mixing Chastetree Berries With Pergolide in Cushing’s Horses – Dr. K’s Horse Sense
4. Prascend® (Pergolide) for Horses with PPID – Mad Barn
5. Ertugliflozin for Horses – Wedgewood Pharmacy
6. Sodium-glucose cotransporter 2 inhibitors in horses – Mad Barn
7. Use of SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia – PMC
8. NSAIDs With SGLT2 Inhibitors May Cause Renal Injury – Medscape
9. Integrating SGLT2is into Management of Equine Metabolic Syndrome – The Horse
10. Thyroid Hormones May Benefit Metabolic Horses – Kentucky Equine Research
11. Thyroid Hormone and Equine Metabolic Syndrome – EquiMed
12. Thyroid Hormone Supplementation Levothyroxine Sodium – Horse Side Vet Guide
13. ECEIM consensus statement on equine metabolic syndrome – PMC
14. Equine Metabolic Syndrome – Merck Veterinary Manual
15. Pharmacokinetics and bioavailability of metformin in horses – AJVR
16. Effects of metformin hydrochloride on blood glucose and insulin – Equine Veterinary Journal
17. Short-term clinical and biochemical responses following treatment with dapagliflozin or ertugliflozin in horses with hyperinsulinemia: A retrospective case series – Domestic Animal Endocrinology (January 2025)
18. SGLT2 Inhibitors (ertugliflozin or canagliflozin) Safety Guidelines – Dengie Horse Feeds (September 2024)
19. Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors – PMC
20. Horse owner experiences and observations with the use of SGLT2i for the management of equine metabolic syndrome and hyperinsulinaemia-associated laminitis – Equine Veterinary Education (2024)
21. Equine metabolic syndrome – Vet Times
22. Sodium-glucose transport protein 2 inhibitor use in the management of insulin dysregulation in ponies and horses – PMC
23. A practical approach to hyperinsulinaemia in horses with equine metabolic syndrome – Equine Veterinary Education (2024)

---

Document Updated: November 2025 | Latest Research Integrated: 2024-2025 SGLT2 Inhibitor Safety Data, Real-World Outcomes, Dapagliflozin Comparison Study